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Summary We studied the mouse NC tumour, a subcutaneously transplanted adenocarcinoma originally of
mammary origin. Measurements per g tissue were made of 17 fatty acids (FAs), the combined amounts of n-3,
n-6, saturated, unsaturated, and total FAs, and of various FA ratios in the tumour, mammary tissue, spleen,
liver and plasma. Compared with mammary tissue from normal mice, tumours of vehicle-treated controls had
less of seven of the FAs and more of two FAs. Mice bearing the NC tumour often had changed (usually
decreased) amounts of FAs in the 'normal' spleen, liver and plasma, but not in mammary tissue. Treatment
with methotrexate (MTX) was studied alone and with indomethacin which can potentiate MTX cytotoxicity.
Indomethacin 1.25 mg kg-' (INDO) increased the amounts of 3/17 tumour FAs and the unsaturated FAs, but
reduced 9/17 FAs, the saturated and the unsaturated FAs in 'normal' mammary tissue, and usually had no
effect on the FAs of other tissues. MTX 2 or 4 mg kg-' (MTX 2 or 4 mg) ± INDO in general partly restored
(increased) the amounts of tumour FAs, and reduced the saturated/unsaturated FA ratio. In the 'normal'
spleen and plasma also, but not in the liver, MTX 2 mg generally somewhat restored the FA composition.
However, as in the liver, the spleen 20:4 and 22:6 (which form prostaglandins and lipid peroxides) did not
increase in the presence of INDO. With MTX 4 mg, some of the plasma and liver FAs decreased, in contrast
to the tumour. There was generally no evidence of MTX potentiation by INDO. These results are discussed in
relation to carcinogenesis, cachexia, and the response to treatment.
Relationships between lipids and cancer are not fully under-
stood. Some epidemiological studies suggest the involvement
of dietary fats in human cancer development (Correa, 1981;
Holm et al., 1989; Prentice et al., 1989; Young & Young,
1989); both the quality and quantity of dietary fats might
influence tumour incidence. In animal studies, linoleic acid
(an n-6 FA) promoted tumour growth and development, with
concomitant increases of eicosanoid synthesis and cell
division, and depression of the immune response (Karmali,
1987). Conversely, diets rich in n-3 FAs inhibited some
cancers, possibly by decreasing arachidonate metabolism
(Karmali, 1987; Abou-EI-Ela et al., 1988).
Cancer cachexia, the weight loss that can accompany
malignancy, involves gross metabolic disturbance. In mice,
this was reduced by dietary manipulation with fish oil (Tis-
dale & Dhesi, 1990) or by treatment with indomethacin
(Gelin et al., 1991). FA changes seen in our experiments
might be relevant to this condition.
Our research into methotrexate (MTX) started because we
found that the cyclo-oxygenase inhibitors flurbiprofen and
indomethacin (INDO) decreased cancer development and
spread (Bennett et al., 1979, 1982). We then demonstrated
that INDO potentiates the anticancer effect of MTX in vitro
and in vivo. The mechanism is not clear, but the effect in vitro
probably does not involve MTX displacement from binding
sites on serum proteins, or inhibition of prostaglandin forma-
tion, cAMP phosphodiesterase or of calcium transport
(Gaffen et al., 1985, 1989; Bennett et al., 1987; Gaffen et al.,
1991). Possibilities examined in the present study are whether
INDO and MTX alone and together affect the fatty acids
(FAs) of malignant and 'normal' tissues, and whether the
potentiation of MTX cytotoxicity involves alteration of
tumour FA composition. We have therefore measured
various FAs in extracts of mouse NC tumour, mammary
tissue, spleen, liver and plasma, and the effects of MTX and
INDO on them.
Ratios of 16:0/16:1, 18:0/18:1, 18:2/20:4, 20:3/20:4, n-6/
n-3 and saturated/unsaturated fatty acids have been
examined for various reasons. The degree of saturation
affects membrane fluidity and permeability (Schlager &
Ohanian, 1980a); 18:0/18:1 is lower in red cell membranes
from cancer patients (Wood et al., 1985); the latter ratio and
16:0/16:1 indicate delta-9-desaturase activity; the 18:2/20:4
ratio reflects delta-6-denaturase, elongase and delta-5-
desaturase activities and eicosanoid production (Fulton, 1984;
Hubbard et al., 1988); 20:3/20:4 reflects delta-5-desaturase
activity; the n-6/n-3 ratio indicates tumour aggressiveness
which is high when n-6 levels are low (Lanson et al., 1990).
Materials and methods
Mouse treatment in vivo
The NC carcinoma used in these studies arose initially in the
mammary region of a WHT/Ht mouse (Hewitt et al., 1976)
and has been transplanted in the same strain since then.
Metastasis to the lungs and mediastinum, local lymphatic
spread and recurrence in the excision scar commonly occur.
Female WHT/Ht mice aged 2-4 months and weighing
24-27 g at the start of the experiment were fed SDS No. 1
modified diet (Special Diet Services Ltd., Essex, UK) and
had free access to water. They were weighed at intervals of
2-4 days starting 10 days before tumour transplantation;
during this short experiment there were no significant
differences between the groups. The two separate experiments
resulted in combined numbers of six to nine mice in each of
the seven groups. On day 0 all but one group of mice were
injected s.c. into the left flank with approximately 106 NC
carcinoma cells (Bennett et al., 1979, 1982). By day 8, 80%
of the tumours were palpable; by day 11 all the mice had
palpable and visible tumours. On days 15-18, the six
tumour-bearing groups received orally administered vehicle
(syrup) alone or containing MTX 2 or 4 mg kg-' (MTX 2 or
4 mg), INDO 1.25 mg kg-' (INDO) alone, or MTX 2 or
4 mg with INDO. A control group without tumour received
only the syrup vehicle.
On day 18, 2.5-7 h after the last drug administration, the
mice were anaesthetised with ether, blood was withdrawn by
cardiac puncture into a tube containing 50 units of heparin,
and the plasma obtained after centrifugation (1,500 g 4°C,
10 min). The mice were killed by cervical dislocation, and the
transplanted tumours, liver, spleen, and mammary tissue
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excised, weighed, and frozen at - 70°C for 1 week prior to
FA analysis. The 'normal' tissues were all macroscopically
free of tumour.
Tissue homogenisation
The frozen tissue was thawed but kept cold in bottles on ice.
Carefully weighed tissue (100-200 mg) was cut into small
pieces, homogenised (100 mg ml'; cold 154 mM NaCl; 30 s;
Silverson homogeniser) and 1 ml of homogenate was removed
for lipid extraction.
Total lipid extraction
The total lipids were extracted according to the method of
Folch et al. (1957). Briefly, to 1 ml tissue homogenate or
plasma were added 2 ml methanol, 100 p1 internal standard
(10-I00 Ag heptadecanoic acid in chloroform), and 3.9 ml
chloroform. The mixture was vortex-mixed for 1 min, centri-
fuged (2,000 g, Omin, 4°C), and the chloroform phase was
removed and evaporated to dryness under a stream of nitro-
gen at 37°C. After dissolving the extract in di-isopropyl
ether/1-butanol (6:4, 2 ml), 1 ml of 50 mM NaCl was added,
vortexed-mixed and centrifuged (2,000g, 10min, 4C). The
upper organic phase containing the total lipids was
evaporated to dryness under nitrogen at 37°C.
Fatty acidsaponification, methylation and analysis
Total lipids were saponified with 2% KOH in methanol and
the FAs methylated with 14% BF3 in methanol. The result-
ing FA methyl esters were extracted with hexane and
analysed by capillary gas chromatography (column:
30 x 0.32 mm bonded FS07, Superox polyethylene glycol;
FID detector temperature 250°C; carrier gas N2 20 ml min-1;
splitter injector, temperature 250°C; oven temperature pro-
gramme: from 150°C to 230°C at 20C min-1; Packard model
436 GC; Shimadzu C-R3A integrator).
Results
Tissue weights
NC tumours from untreated mice weighed 794 mg (715-1,000)
at day 18. Treatment with MTX 4 mg kg-' (MTX 4 mg)
alone or with indomethacin 1.25 mg kg-' (INDO) reduced
the tumour weights by 44 and 57% respectively, whereas
INDO alone or with MTX 2 mg had little or no effect (Table
I).
At day 18 the spleens from normal mice given vehicle
weighed 72 mg (30-110), whereas those from mice with un-
treated tumours were 85% heavier (P <0.003). Treatment
with MTX 4 mg + INDO decreased the spleen weight to 109
and 85 mg (51 and 18% respectively more than in normal
mice). MTX 2 mg ± INDO tended to reduce the spleen
weight, but INDO alone had no effect (Table I).
The weight of livers from normal mice was 1.21 g
(1.11-1.32), about the same as in the cancer-bearing groups,
and was unchanged by drug treatment.
Fatty acid changes
Since there are seven groups each with measurements of
17 FAs, combined amounts of n-3, n-6, saturated, unsaturated
and total FAs, and calculations of various ratios, it is to be
expected that by chance some analyses will indicate a statisti-
cally significant difference when none really exists (a Type I
error). Nevertheless, it seems that at least some of the
treatments resulted in genuine changes. Because of the large
amount of data, we have selected for discussion the aspects
mainly related to tumour FAs, the effects of the tumour on
normal tissue FAs, and to a possible MTX/INDO interac-
tion. Details of all aspects are presented in the Tables.
The FAs in 'normal' tissues from tumour-bearing vehicle-
treated mice are compared with normal controls (i.e. no
cancer) that received only vehicle. FAs in the drug-treated
groups are compared with tissues from vehicle-treated
tumour-bearing mice.
Tumourfatty acids
Table II shows the amounts g-' of FAs in the total tumour
Statistics lipids.
Results are presented as median values and interquartile
ranges or as per cent median changes. The Mann-Whitney
U-test (2-tailed) was used for comparisons of FA content.
Only P values of at most 0.1 are shown in the tables, and
unqualified statements in the text imply a P value of at most
0.05. All doses are mg kg- '; for simplicity this is usually
shortened in the text by omitting the kg-' from the MTX
doses, and by referring to INDO 1.25 mg kg-' as INDO.
Comparison of mice with and without tumours Compared
with mammary tissue from normal mice the tumours had less
g-I of 7/17 FAs, more of 2/17 FAs and overall less combined
amounts of n-3, total, unsaturated and saturated FAs.
Drug effects Treatment altered the amounts of tumour FAs,
and the changes were often greater with MTX 4 mg than
with MTX 2 mg (Table II). INDO alone also caused some
Table I Mouse tumour spleen and liver weights with different treatments
Tumour Spleen Liver
Drugs mgkg-' (mg) (mg) (mg)
Vehicle 794 (715-1000) 133 (125-165) 1350 (1250-1480)
MTX 2 789 (729-932) 101 (92-121) 1260 (1250-1310)
MTX 4 449 (359-569)' 109 (94-118)b 1250 (1180-1300)
INDO 1.25 655 (488-788) 139 (129-158) 1340 (1320-1390)
MTX 2+INDO 1.25 595 (538-693) 103 (97-118) 1290 (1240-1420)
MTX 4 + INDO 1.25 335 (219-492)' 85 (69_90)c 1250 (1240-1260)
Vehicle-treated normal mice 72 (30-110)C 1210 (1110-1320)
Tissue weights (mg) are shown as medians with interquartile ranges in parentheses.
Comparisons of tissues weights with vehicle-treated cancer-bearing mice are: ap<0.05;
bp <0.02; cP <0.003. Normal mice had a median spleen weight of 72 mg which increased
by 85% in the presence of tumour (to a median of 133 mg) and was almost normal (85 mg,
9.7% bigger) in mice given MTX 4 mg kg-' + INDO 1.25 mgkg-'. The lower median
tumour and spleen weights with MTX 4 mg + INDO were not significantly different from
those with MTX 4 mg alone. Normal mice had a median liver weight of 1.21 g. This was not
significantly affected by the presence of tumour or the treatments administered. Vehicle-treated
cancer group n = 9; vehicle-treated non-cancer group n = 12; other groups n = 6.FATTY ACIDS IN MURINE MALIGNANCY AND AFTER THERAPY 165
Table II Amounts of FAs in the NC tumour total lipids, changes with treatment, and comparison
with mammary tissue from nonnal mice
Drugs mgkg-':
Fatty acids
14:0
16:0
16:1
18:0
18:1
18:2
18:3
18:4
20:0
20:1
20:2
20:3
20:4
20:5
22:2
22:4
22:6
Vehicle
tLgg-'
216 (186-303)
2670 (2060-3630)
627 (512-1030)
1960 (2080-1050)
2750 (2440-3920)
861 (777-1280)
14 (10-19)
22 (22-30)
21 (9-25)
45 (30-65)
197 (112-269)
68 (64-120)
2240 (1170-2390)
124 (80-155)
167 (137-204)
313 (158-361)
370 (294-536)
n-3 589 (375-732)
n-6 4120 (2460-4270)
Saturated 4990 (3300-5910)
Unsaturated 8150 (6210-9580)
Total
Ratios:
16:0/16:1
18:0/18:1
18:2/20:4
20: 3/20:4
n-6/n-3
Saturated/
unsaturated
13100 (9510-15400)
4.0 (3.4-4.6)
0.5 (0.5-0.6)
0.6 (0.4-0.7)
0.05 (0.04-0.05)
5.8 (5.0-7.0)
0.6 (0.58-0.60)
112 114 93 108 108 305d
134c 197b 107 163c 109 136a
123a 252a 114 184c 120 18Id
145b 382b 140b 240c 142a 225d
137a 174a l30a 220c 132 208d
104
91
90
100
77b 81 76
19C 59 39
853C 185 262
100 80 100
84a
50c
277c
80
148b 244a 146a 159b 156c
87c 72c 83b 78b 80C
107
35d
408d
140a
61
83
Calculated amounts of fatty acids (fg g- ', to three significant figures) are shown for the tumours of
vehicle-treated mice (n = 9) as median values with interquartile ranges in parentheses. Mammary tissue
from normal mice (n = 6) and the results of treatment (n = 6) are expressed as percentages of the
vehicle-treated tumour-bearing controls. P values compared with vehicle treated cancer-bearing mice;
a<0.1, b<O.05, C<0.02, d<O.OO2. The ratios of some FAs are shown at the bottom of the table.
increases, and the effect of MTX 2 mg ± INDO usually ap-
proximated to the sum of the changes obtained with the two
drugs given separately. In contrast, INDO appeared to
counteract the effect of MTX 4 mg.
Most of the treatments reduced the ratio of tumour
saturated/unsaturated FAs compared with the control
tumours, because the amounts of unsaturated FAs tended to
increase more than the saturated FAs. Combined amounts of
the n-6 polyunsaturated FAs (18:2, 20:2, 20:3, 20:4, 22:2
and 22:4) increased with MTX 2 mg ± INDO or MTX 4 mg
alone. The n-6/n-3 ratio also increased, because the combined
amounts of the n-3 FAs (18:3, 18:4, 20:5 and 22:6) were not
significantly changed.
In the MTX 4 mg ± INDO groups the ratio of tumour
18:2/20:4 was generally greater, while 18:0/18:1 was less,
compared with control tumours.
Mammaryfatty acids
These results are shown in Table III.
Comparison of mice with and without tumours Amounts of
FAs and the various ratios examined in the mammary tissue
from tumour-bearing vehicle-treated and normal mice were
similar.
Drug effects Treatment with MTX 2 or 4 mg alone had
little or no effect of the 'normal' mammary FA composition.
INDO alone decreased the amounts of nine FAs (14:0, 16:0,
16:1, 18:1, 18:2, 18:3, 20:1, 20:2, 22:4), and reduced the n-6,
saturated, unsaturated and total FAs, and the 18:2/20:4 and
n-6/n-3 ratios. Only the 16:0/16: 1 ratio increased with
INDO. The results with MTX 2 or 4 mg ± INDO were
usually about midway between the median FA changes with
either drug alone.
Plasmafatty acids
These results are shown in Table IV.
Comparison of mice with and without tumours Plasma from
the cancer-bearing mice had smaller amounts of 4/17 FAs
(14:0, 18:0, 18:4, 20:0) and more 18:1 and 18:3. Both
groups contained similar amounts of total plasma FAs, but
the tumour-bearers had less saturated FAs.
Drug effects In the untreated cancer group, amounts of
plasma 14:0, 18:0, 18:4 and 20:0 were below normal,
whereas 18:1 and 18:3 were raised. MTX 2 mg ± INDO in
general appeared to inhibit the falls in the unsaturated FAs,
and they increased the saturated/unsaturated and the 18:0/
18:1 ratios. In contrast, MTX 4 mg ± INDO did not 'pro-
tect' against the cancer-induced falls, and actually reduced
the amounts of several FAs (36% less total FAs; 29-41%
less unsaturated FAs). All treatments increased the 16:0/16:1
ratio, but otherwise INDO usually caused no change.
Liverfatty acids
These results are shown in Table V.
Comparison of mice with and without tumours Livers of the
tumour-bearing vehicle-treated mice had less of eight FAs
(14:0, 16:1, 18:1, 18:2, 18:3, 20:1, 20:2, 20:3), unsaturated,
MTX
2
140
136
136
1 17a
17b
178b
164
86
176c
236c
161C
j97c
118c
100
124
119
129
MTX
4
345
379a
524a
100
691 a
752b
691c
305c
95
473b
76
144
74
81 a
97
67
101
INDO
1.25
140
136
175a
87
192b
209a
286c
150
100
207b
119
124
80
89
125
77
97
MTX 2
+ INDO
258b
247c
352b
106
355b
420c
771
227d
133b
313c
112
196
108
93
69b
117
126
MTX 4
+ INDO
151
143
1 84b
97
197b
222c
364c
218a
100
164
69
116
80
59
91
79
110
No tumour
normal
198c
258d
274c
116
332d
426d
828d
132
90
262a
43
150
65
75
48c
34d
357d166 Z. YAZICI et al.
Table III Amounts of FAs in the total lipids of normal mammary tissue from NC tumour-bearing and
non-tumour-bearing WHT/Ht mice
Drugs mgkg-': Vehicle MTX MTX INDO MTX 2 MTX 4 No tumour
Fatty acids gg-1 2 4 1.25 + INDO + INDO normal
14:0 430 (212-531) 82 50 29b 49 29b 100
16:0 7770 (3990-8380) 81 52a 33C 55 42b 89
16:1 1820 (909-2210) 92 82 68c 85 76 95
18:0 1650 (1340-1990) 102 91 75 93 83 106
18:1 5830 (5130-12000) 165 71 44b 100 72 157
18:2 5430 (2160-6320) 74 45a 21c 49 30b 68
18:3 195 (67-215) 66 34 14b 39 1ga 60
18:4 25 (22-30) 116 124a 104 76c 104 116
20:0 13 (7-16) 139 92 54 92 54a 146a
20:1 177 (61-202) 95 59 16c 48 24a 67
20:2 85 (36-104) 93 73 49b 67 53 99
20:3 98 (50-100) 106a 101 68 102 71 104
20:4 1650 (1010-1710) 1i1 a 100 72 112a 78 89
20:5 92 (47-101) 69 78 48 75 52a 101
22:2 128 (111-204) 80 84 84 57b 134 63a
22:4 163 (60-175) 98 75 53b 77 51 66
22:6 1500 (1090-1830) 116 140 85 143c 103 88
n-3 1860 (1190-2130) 115 123 74 122C 92 96
n-6 7560 (3260-8500) 84 61 35b 65 43 74
Saturated 10200 ((5440-1280) 81 56a 39b 59 46a 89
Unsaturated 16900 (10600-23900) 115 84 42b 83 58 108
Total 29700 (15900-34500) 93 69 37b 67 49 92
Ratios:
16:0/16:1 4.3 (3.7-5.1) 97 122a 164c 121 139 100
18:0/18:1 0.3 (0.2-0.5) 68 108 192a 104 128 76
18:2/20:4 3.1 (2.2-4.1) 70 52a 35c 47a 49a 79
20:3/20:4 0.06 (0.05-0.06) 100 100 100 83 83 117a
n-6/n-3 3.3 (2.7-4.7) 95 61c 63c 63b 68 107
Saturated/ 0.5 (0.4-0.6) 80a 86 112 94 104 98
unsaturated
Calculated FA amounts (1sg g given to three significant figures) are shown for vehicle-treated mice
(n = 9) as median values with interquartile ranges in parentheses. Results of treatment (n = 6) are per
cent of the vehicle-treated tumour-bearing controls, to at most three significant figures. P values a<0.1,
b<0.05, C<0.02, d<0.002. Ratios of some FAs are shown at the bottom of the table. P values for
MTX 2 mg vs MTX 2 mg + INDO were 0.066 for 18:2/20:4, and 0.03 for n-6/n-3.
total and n-6 FAs. Ratios of 16:0/16:1, 18:0/18:1 and
saturated/unsaturated FAs were above normal, whereas n-6/
n-3 was less.
Drug effects The total amounts of FAs extracted from the
liver were similar in the treatment and control groups. No
treatment counteracted the depression of FAs by the tumour,
and any statistically significant changes of combined amounts
or ratios were small.
Spleenfatty acids
These results are shown in Table VI. As in all the tissues, the
amounts are g-', but this is specified again here because of
some changes in spleen weight (increased in the tumour-
bearing group, and reduced towards normal by MTX
4mg± INDO).
Comparison of mice with and without tumours In tumour-
bearing mice, the content of total spleen FAs g-' was less
than from liver and mammary tissue, similar to tumour, and
more than from plasma. Amounts of ten FAs were less in the
spleens of tumour-bearing mice (14:0, 16:0, 16:1, 18:1, 18:2,
18:3, 20:1, 20:3, 20:4 and 22:4), but there was more 20:5.
The cancer group had higher ratios of spleen 16:0/16:1,
18:0/18:1, saturated/unsaturated FAs, but lower ratios of
18:2/20:4 and n-6/n-3.
Drug effects MTX 2 mg + INDO increased 6/9 of the
tumour-depressed spleen FAs towards normal (14:0, 16:1,
18:1, 18:2, 18:3, 20:1) and tended to 'normalise' the com-
bined amounts of unsaturated FAs, total FAs, 16:0/16:1,
18:0/18: 1, n-6/n-3, and saturated/unsaturated FAs). MTX
2 mg alone tended to 'normalise' three depressed FAs (20:3,
20:4, 22:4), n-6 unsaturated FAs, and the total FAs. Com-
pared to MTX 2 mg + INDO there were fewer changes with
MTX 4 mg + INDO, and some of these were in the opposite
direction. INDO alone had no significant effect, but tended
to inhibit the effect of MTX 2 mg on n-3, n-6, 20:3, 20:4,
22:4 and 22:6 FAs.
Discussion
Modification of cellular FA composition may affect physical
properties such as membrane fluidity and permeability, and
certain cellular functions including transport systems, recep-
tor binding, and eicosanoid production (De Kruyff et al.,
1973; King et al., 1977; King & Spector, 1978). These might
change the responses of cells to hormones, and their suscepti-
bility to immune attack (Burns et al., 1979; Fulton & Heppner,
1985; Guffy et al., 1984; Schlager & Ohanian, 1979, 1980a,b).
Fatty acid changes in malignancy
Wood et al. (1985) found increased desaturation of stearic
(18:0) to oleic acid (18:1) in red cell membranes from
patients with colorectal cancer, and a consequently decreased
18:0/18:1 ratio. We found a similar change in the plasma
18:0/18:1 ratio in the tumour-bearing mice, but the reverse in
the liver and spleen. Tumour-bearing mice usually had less of
some FAs in the spleen, liver and plasma, but there was littleFATTY ACIDS IN MURINE MALIGNANCY AND AFTER THERAPY 167
Table IV The FA content in total plasma lipids from NC tumour-bearing and non-tumour bearing
WHT/Ht mice
Drugs mgkg-':
Fatty acids
14:0
16:0
16:1
18:0
18:1
18:2
18:3
18:4
20:0
20:1
20:2
20:3
20:4
20:5
22:2
22:4
22:6
n-3
n-6
Saturated
Unsaturated
Total
Ratios:
16:0/16:1
18:0/18:1
18:2/20:4
20:3/20:4
Vehicle
g.gg'-
40.4 (24.5-44.9)
797.0 (544-977)
63.6 (45.2-70.4)
588.0 (299-602)
473.0 (436-588)
495.0 (378-554)
7.6 (7.1-10.5)
10.4 (7.4-14.6)
5.6 (2.3-5.7)
6.0 (4.5-7.5)
19.4 (11.0-20.8)
23.0 (21.5-24.5)
426.0 (281-435)
62.0 (61.0-85.4)
52.9 (31.9-60.8)
5.8 (4.8-6.9)
120.0 (99.1-137)
203.0 (198-250)
1020.0 (722-1070)
1440.0 (871-1650)
1800.0 (1400-1980)
3280.0 (2270-3630)
12.5 (11.7-14.2)
0.9 (0.8-1.1)
1.4 (1.2-1.4)
0.06 (0.06-0.07)
MTX
2
1 Iga
113
71
133d
113
97
80a
164a
155d
97
58a
94
102
92b
82
119
107
MTX
4
91
77
39d
95
61C
63b
43c
102
200
57
67
80b
87
82d
83
52a
88
INDO
1.25
60
67
56c
61
85
80
70c
122
36
70
60
86
79
109
67
67a
88
MTX 2
+ INDO
109
103
72
l113b
90
86
59b
I53a
136c
62
73
78
89
77c
92
105
86
MTX 4
+ INDO
72
60b
53c
69
53c
57b
53c
117
50
59
47c
62c
68
70b
78
66
57a
104 88 98 87b 63b
98 76b 78a 92 63
122C 84
100 71b
109 77
64
81
72
112
88
98
68
59c
64b
No tumour
normal
139c
100
70
140d
82c
70
65d
239c
179C
68
81
110
95
98
91
128a
85
99
88
118c
84
98
148c 192d 158b 133b 128b 125c
161c 197a 130 169c 133 24Id
87a 67d 87 84 80c 69d
83a 83b 117 83a 83 100
n-6/n-3 4.4 (4.1-4.9) 111 100 98 120b 114 105
Saturated/ 0.8 (0.6-0.8) 124C 115 103 125d 111 145d
unsaturated
Calculated FA amounts (sg ml-', given to three significant figures) are shown for vehicle-treated
group of mice (n = 9) as median values with interquartile ranges in parentheses. The results of the
treatment groups (n = 6, except for n = 5 with INDO alone, normal mice without tumour, and the
20:0 FA/MTX 4 mg kg-' kg-' n = 5) are expressed as percentages of the vehicle-treated
tumour-bearing controls. P values a<0.1, b<O.05, c<0.02, d<O.002. The ratios of some FAs are
shown at the bottom of the table.
or no change in 'normal' mammary tissue (the site of tumour
origin; Hewitt et al., 1976).
Fatty acid changes and the anticancer effect ofcytotoxic drugs
FA changes can affect anticancer therapy, and vice-versa.
Cells enriched with polyunsaturates accumulated more
adriamycin and MTX (Burns et al., 1979; Burns & North,
1986), and effective cytotoxic drugs caused an overall rise in
the unsaturated FA content of cells (Schlager et al., 1980b).
In our experiments MTX increased the tumour content of
unsaturated FAs, and this effect might alter the cell membrane
permeability and thickness (Schlager & Ohanian, 1980a,b).
Methotrexate/indomethacin interaction
The MTX/INDO interaction is important because INDO
potentiates both the MTX-induced prolongation of survival
of mice with NC tumours, and the killing of NC cells and
human breast cancer cells in culture (Bennett et al., 1987).
The mechanism(s) are not fully understood, but we recently
found that INDO potentiated the changes in FA composition
induced by MTX in cultured NC cells (Soydan et al., 1991).
However, potentiation rarely occurred in the present in vivo
experiments.
Our previous results in vitro indicate that the effect does
not involve MTX displacement from binding sites on serum
proteins, or inhibition of prostaglandin formation, cAMP
phosphodiesterase or of calcium transport (Gaffen et al.,
1985, 1989; Bennett et al., 1987; Gaffen et al., 1991). How-
ever, inhibition of prostaglandin synthesis seems to explain
the prolongation of survival by INDO in NC tumour-bearing
mice (Bennett et al., 1985), and we have not excluded the
possibility that this mechanisms may contribute to the poten-
tiation of MTX cytotoxicity in vivo. The spleen can synthesise
large amounts of prostanoids such as PGE2, PGI2 and
thromboxane A2 (Pace-Asciak & Rangaraj, 1977; Hidaka et
al., 1983), and these prostanoids might affect the host re-
sponse to the tumour (Bennett, 1982). In the NC tumour and
spleen, amounts of 20:4 (the precursor of the 2-series prosta-
glandins) increased somewhat with MTX 2 mg. Perhaps the
potentiation of MTX cytotoxicity by INDO in vivo (Bennett
et al., 1987) involves a decrease in the formation of
immunosuppressive PGE2, particularly since MTX itself
causes immunosuppression (Jackson, 1984; Chabner et al.,
1985), and cytotoxic drugs can increase prostaglandin release
(Levine, 1977; Berstock et al., 1980).
Prostaglandins are not the only lipids that can influence
the immune system, and linoleate alone or in metabolic
relationships with arachidonate and prostaglandins might be
involved (Plescia et al., 1975). Mammary tumour cells syn-
thesise primarily 18:3, 20:3 and 20:4 FAs from 18:2 (Chap-
kin et al., 1989), indicating the presence of desaturase and
elongase enzymes. In our cancer-bearing mice, MTX
4 mg + INDO decreased the 18:2/20:4 ratio in the spleen,
but increased it in the tumour. These results might reflect
changed enzymic activities and/or prostaglandin production
(Fulton, 1984; Hubbard et al., 1988).168 Z. YAZICI et al.
Cachexia
The cachexia of malignancy is associated with weight loss
and changes in body biochemistry which appear to be
tumour-driven. Unlike starvation in a non-tumour-bearing
host, the condition does not respond to 'corrective' nutrition.
FA metabolism is involved, but the extent of this derange-
ment is not known. The changes of tissue FAs that we
obtained in response to the tumour and to therapy may be
relevant to cancer cachexia.
In conclusion, FA changes occurred not only in the NC
tumour compared to the normal mammary tissue from the
same strain of mice in which it originally arose several years
ago, but also in 'normal' tissues of cancer-bearing mice. The
tumour changes relate in unexplained ways to carcinogenesis,
and the 'normal' tissue FA alterations might relate to
cachexia. It seems that some of these changes are reduced by
treatment vith MTX ± INDO, particularly with the lower
MTX dose of 2 mg kg-'.
Table V The amounts of FAs in total liver lipids from NC tumour-bearing and non-tumour-bearing
WHT/Ht mice
Drugs mg kg-':
Fatty acids
14:0
16:0
16:1
18:0
18:1
18:2
18:3
18:4
20:0
20:1
20:2
20:3
20:4
20:5
22:2
22:4
22:6
Vehicle
ig g
132 (106-162)
7740 (555-7870)
500 (300-712)
3450 (3260-3480)
6150 (4090-6540)
4420 (2940-5340)
56 (46-88)
20 (11-21)
8 (7-10)
72 (36-90)
143 (90-155)
330 (268-371)
6520 (4000-6850)
631 (586-731)
ND
120 (87-131)
3020 (2240-3180)
n-3 3730 (3070-3930)
n-6 12200 (6930-12500)
Saturated 11200 (8280-15600)
Unsaturated 22300 (21700-24000)
Total
Ratios:
16:0/16:1
18:0/18:1
18:2/20:4
20:3/20:4
n-6/n-3
Saturated/
unsaturated
33800 (20900-35600)
14.3 (11.3-16.6)
0.6 (0.5-0.8)
0.8 (0.6-0.?)
0.06 (0.05-0.06)
3.0 (2.9-3.6)
0.5 (0.5-0.6)
112 75 92 95 76 96
1 1OC 78 84 102 80 113c
91 80 84 90 88 103
109 77 86 100 83 132C
100 77 84 97 84 121C
114
102
78
72C
143a 109
121 126
82 91
83b 102
106
85
89
84a
109
114
94
93
66c
45d
119
109
114 115 108 118a 115 122b
81c 104 104 89c 110 77d
MTX
2
99
84
80
103
99
110
121
105
75c
108
97
107
117c
738
ND
108
1 14a
MTX
4
98
75
57a
92a
73
83
61a
110
88
60
63b
76
84
62c
ND
59a
79
INDO
1.25
95
78
79
98
79
85
105
l 15b
100
96
88
87
88
98
ND
69a
90
MTX 2
+ INDO
95
89
96
88
103
109
107
115
88
82
81
93
gb
65a
ND
95
100
MTX 4
+ INDO
108
82
85
94
86
89
79
110
138
85
68
89
83
79
ND
70
77
No tumour
normal
153b
110
186c
87a
l174d
140c
220b
110
100
186C
122C
l127b
104
115
ND
88
93
The amounts of FAs (ug g- , given to three significant figures) are shown as median values with
interquartile ranges in parentheses. The treatment groups (n = 6, including the normal mice without
tumour) are expressed as percentages of the vehicle-treated tumour-bearing controls (n = 9). P values
<0.1, b<0.05, C<0.02, d<0.002. 20:2 was not detected (ND) in any of the groups examined. Fatty
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Table VI Fatty acid amounts in total spleen lipids from NC tumour-bearing and non-tumour
WHT/Ht mice
Drugs mgkg-': Vehicle MTX MTX INDO MTX 2 MTX 4 No tumour
Fatty acids igg- g 2 4 1.25 + INDO + INDO normal
14:0 163 (112-194) 155 130 88 201c 98 215c
16:0 2780 (2630-2880) 105 114 100 97 107 118a
16:1 303 (220-336) 157a 118 92 200c 68a 225c
18:0 1310 (1250-1850) 115 136 122 93 222 114
18:1 3700 (2200-4210) 173 110 83 181c 54a 214d
18:2 1010 (974-1160) 138a 110 103 144b 99 180c
18:3 39 (15-44) 182 110 77 203C 44 249d
18:4 ND ND ND ND ND ND ND
20:0 ND ND ND ND ND ND ND
20:1 87 (48-95) 159a 98 70 145c 68 176c
20:2 95 (89-99) 115 97 98 98 106 111
20:3 136 (127-144) 118b 105 97 102 110 118d
20:0 3040 (2860-3110) 118d Iloa 98 100 115b 113b
20:5 132 (126-176) 77b 82a 127 86 102 81c
22:2 ND ND ND ND ND ND ND
22:4 363 (314-398) 119C 87 93 85 98 118b
22:6 871 (809-953) 130b 110 106 90 118b 106
n-3 1090 (1020-1120) 121b 105 101 89 110 1Q4a
n-6 4730 (4610-4880) 118d 107 100 107 109 126c
Saturated 4380 (3920-4760) 112 123 103 94 89 117b
Unsaturated 9220 (8090-10600) 150b 109 101 144c 97 174d
Total 13100 (12700-15000) 145b 120 105 131c 102 162d
Ratios:
16:0/16:1 8.4 (7.5-12.0) 73 121 121 52d 200 55d
18:0/18:1 0.4 (0.3-0.8) 74 202 189 59b 435b 53d
18:2/20:4 0.4 (0.3-0.4) 89 92 89 124 73c 138
20:3/20:4 0.05 (0.05-0.05) 91a 94 104 96 94c 102
4.4 (4.1-4.5) 105 106 93 116C 97 115b
n-6/n-3 0.4 (0.4-0.6) goa 122 120 78d l81a 81d
unsaturated
The amounts of FAs (g g-', given to three significant figures) are shown as median values with
interquartile ranges in parentheses. The treatment groups (n = 6, except MTX 2 mg kg-' and MTX
4 mg kg-' + INDO n = 5), and the normal mice without tumour, are expressed as percentages of the
vehicle-treated tumour-bearing controls (n = 9). P values a<0.1, b<o.os, c<0.02, d<0.002. 18:4, 20:0,
22:2 were not detected (ND) in any of the groups examined. Fatty acid ratios are shown at the bottom
of the table.
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